Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $11.79 and last traded at $11.77, with a volume of 52140 shares trading hands. The stock had previously closed at $12.20.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group initiated coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences currently has an average rating of "Buy" and an average price target of $30.50.
View Our Latest Research Report on Tyra Biosciences
Tyra Biosciences Price Performance
The company has a market capitalization of $567.26 million, a PE ratio of -6.96 and a beta of 1.05. The company has a 50 day moving average of $14.22 and a two-hundred day moving average of $17.85.
Insiders Place Their Bets
In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of the business's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the sale, the director now directly owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Tyra Biosciences
Hedge funds have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences in the fourth quarter worth $31,000. US Bancorp DE bought a new stake in Tyra Biosciences in the fourth quarter worth $50,000. BNP Paribas Financial Markets bought a new stake in Tyra Biosciences in the fourth quarter worth $60,000. Aquatic Capital Management LLC bought a new position in shares of Tyra Biosciences during the fourth quarter valued at $64,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares in the last quarter. 84.14% of the stock is owned by institutional investors.
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
